VOR
Vor Biopharma Inc

1,766
Mkt Cap
$162.28M
Volume
159,125.00
52W High
$65.80
52W Low
$2.62
PE Ratio
-0.02
VOR Fundamentals
Price
$8.21
Prev Close
$7.95
Open
$8.37
50D MA
$24.64
Beta
1.16
Avg. Volume
463,280.57
EPS (Annual)
-$34.03
P/B
-0.03
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Wedbush Predicts Vor Biopharma's Q4 Earnings (NASDAQ:VOR)
Vor Biopharma Inc. (NASDAQ:VOR - Free Report) - Research analysts at Wedbush issued their Q4 2025 EPS estimates for shares of Vor Biopharma in a research note issued to investors on Tuesday, November...
MarketBeat·4h ago
News Placeholder
More News
News Placeholder
Wedbush Initiates Coverage on Vor Biopharma (NASDAQ:VOR)
Wedbush restated a "neutral" rating and issued a $9.00 price target on shares of Vor Biopharma in a research note on Tuesday...
MarketBeat·2d ago
News Placeholder
Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know
Vor Biopharma (VOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·3d ago
News Placeholder
Vor Biopharma (NASDAQ:VOR) Posts Quarterly Earnings Results, Misses Expectations By $0.27 EPS
Vor Biopharma (NASDAQ:VOR - Get Free Report) announced its earnings results on Thursday. The company reported ($3.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates...
MarketBeat·13d ago
News Placeholder
Vor Biopharma (NASDAQ:VOR) Price Target Cut to $32.00 by Analysts at HC Wainwright
HC Wainwright decreased their price target on Vor Biopharma from $55.00 to $32.00 and set a "buy" rating for the company in a research note on Friday...
MarketBeat·13d ago
News Placeholder
Zacks Research Upgrades Vor Biopharma (NASDAQ:VOR) to "Hold"
Zacks Research raised shares of Vor Biopharma from a "strong sell" rating to a "hold" rating in a research report on Tuesday...
MarketBeat·14d ago
News Placeholder
Investors Buy High Volume of Vor Biopharma Put Options (NASDAQ:VOR)
Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders acquired 8,702 put options on the company. This represents an increase of...
MarketBeat·16d ago
News Placeholder
Vor Biopharma Prices Public Offering Of 10 Mln Shares At $10.00/shr
(RTTNews) - Vor Biopharma Inc. (VOR) announced the pricing of an underwritten public offering of 10 million shares of its common stock at a public offering price of $10.00 per share...
Nasdaq News: Markets·18d ago
News Placeholder
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Hold" from Analysts
Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) has been assigned an average recommendation of "Hold" from the eleven brokerages that are covering the company, MarketBeat reports. Two equities...
MarketBeat·21d ago
News Placeholder
Vor Bio Stock Jumped 19% Today And Retail Investors Are Eyeing A Breakout Rally: Here’s What’s Happening
A late-stage clinical study in China conducted by Vor Bio’s collaborator RemeGen Co., which is evaluating Telitacicept in adults with primary Sjögren's disease, achieved the primary endpoint of improving disease activity compared to placebo.
Stocktwits·4mo ago

Latest VOR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.